S01LA Antineovascularisation agents
ATC group of level 4 – chemical subgroup · in plain English: eye medicines
This site has the patient leaflet or the SPC of 29 medicines in this group and its subgroups.
- 19 prescription only (POM)
- 2 no longer supplied or not available
Place in the ATC classification
- S Sensory organ drugs 363 medicines
- S01 Ophthalmologicals 345 medicines
- S01L Ocular vascular disorder agents 29 medicines
-
S01LA Antineovascularisation agents 29 medicines
- S01LA01 verteporfin 1 medicine
- S01LA03 pegaptanib 1 medicine
- S01LA04 ranibizumab 12 medicines
- S01LA05 aflibercept 13 medicines
- S01LA06 brolucizumab 2 medicines
-
S01LA Antineovascularisation agents 29 medicines
- S01L Ocular vascular disorder agents 29 medicines
- S01 Ophthalmologicals 345 medicines
2 more subgroups have no medicine with a leaflet on this site.
Active substances in the group
- Aflibercept 13 medicines
- Brolucizumab 2 medicines
- Pegaptanib 1 medicine
- Ranibizumab 12 medicines
- Verteporfin 1 medicine
Medicines in the group and its subgroups
Other names of the ATC group
- Czech: S01LA Látky určené k léčbě neovaskularizace v oblasti oka
- French: S01LA médicaments contre la néo-vascularisation oculaire
- German: S01LA Antineovaskuläre Mittel
- German: S01LA Antineovaskuläre Mittel
- Italian: S01LA Sostanze antineovascolarizzanti
- Polish: S01LA Substancje do leczenia neowaskularyzacji w oku
- Turkish: S01LA Antineovaskülarizasyon ajanları
- Portuguese (Brazil): S01LA Fármacos antineovascularização
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group S01LA
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.
